abstract |
The present invention comprises human monoclonal antibodies to bind to PD-Li (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-Li inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections. |